nivolumab,bevacizumab
roche,bms
['nivo', 'nivacor', 'beva', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'bevacizumab', 'nivolumab', 'bristol']
 2022 updates:
the outcomes from the #nivacor trial presented at #asco 2022 by suggest that #nivolumab in combination with #folfoxiri, #bevacizumab can be effective in ras/braf mutated mcrc regardless of mmr status. find out more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry